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CLINICAL RESEARCH ARTICLE
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Psychology, Leiden University, Leiden, The Netherlands; dBureau Bêta, Nijmegen, The Netherlands; eDepartment of Psychiatry, Radboud
University Medical Centre, Nijmegen, The Netherlands; fPsychotrauma Expertise Centre (PSYTREC), Bilthoven, The Netherlands
ABSTRACT
Background: Suboptimal response and high dropout rates leave room for improvement of
trauma-focused treatment (TFT) effectiveness in ameliorating posttraumatic stress disorder
(PTSD) symptoms.
Objective: To explore the effectiveness and safety of intensive prolonged exposure (iPE)
targeting chronic PTSD patients with a likely diagnosis of ICD-11 Complex PTSD following
multiple interpersonal trauma and a history of multiple treatment attempts.
Method: Participants (N = 73) received iPE in 12 × 90-minute sessions over four days
(intensive phase) followed by four weekly 90-minute booster prolonged exposure (PE)
sessions (booster phase). The primary outcomes, clinician-rated severity of PTSD symptoms,
and diagnostic status (Clinician-Administered PTSD Scale; CAPS-IV) were assessed at base-
line, post-treatment, and at three and six months. Treatment response trajectories were
identified and predictors of these trajectories explored.
Results: Mixed model repeated measures analysis of CAPS-IV scores showed a baseline-to-
posttreatment decrease in PTSD symptom severity (p < .001) that persisted during the three-
and six-month follow-ups with large effect sizes (Cohen’s d > 1.2); 71% of the participants
responded. None of the participants dropped out during the intensive phase and only 5%
during the booster phase. Adverse events were extremely low and only a minority showed
symptom exacerbation. Cluster analysis demonstrated four treatment response trajectories:
Fast responders (13%), Slow responders (26%), Partial responders (32%), and Non-responders
(29%). Living condition and between-session fear habituation were found to predict out-
come. Participants living alone were more likely to belong to the Partial responders than to
the Non-responders cluster, and participants showing more between-session fear habituation
were more likely to belong to the Fast responders than to the Non-responders cluster.
Conclusions: The results of this open study suggest that iPE can be effective in PTSD
patients with multiple interpersonal trauma and after multiple previous treatment attempts.
In addition, in this chronic PTSD population iPE was safe.
Terapia de exposición prolongada intensiva para pacientes con PTSD
crónico después de traumas múltiples y múltiples intentos de
tratamiento
Planteamiento: La respuesta subóptima y las altas tasas de abandono dejan margen para la
mejora de la eficacia del tratamiento centrado en el trauma (TCT) en la mejora de los
síntomas del trastorno por estrés postraumático (TEPT).
Objetivo: explorar la efectividad y la seguridad de la exposición prolongada intensiva (EPI)
dirigida a pacientes con TEPT crónico con un probable diagnóstico de TEPT complejo de la
CIE-11 después de múltiples traumas interpersonales y un historial de múltiples intentos de
tratamiento.
Método: Los participantes (N = 73) recibieron EPI en 12 sesiones de 90 minutos durante
cuatro días (fase intensiva) seguidas de cuatro sesiones semanales de exposición prolongada
(EP) de refuerzo de 90 minutos (fase de refuerzo). Los resultados principales, la gravedad de
los síntomas del TEPT evaluados por el clínico y el estado diagnóstico evaluados por el
clínico (Escala de TEPT administrada por el clínico, CAPS-IV, por sus siglas en inglés) se
evaluaron al inicio, después del tratamiento, y a los tres y seis meses. Se identificaron las
trayectorias de respuesta al tratamiento y se exploraron los predictores de estas trayectorias.
Resultados: Los análisis de medidas repetidas de las puntuaciones de CAPS-IV desde un
modelo mixto mostraron una disminución de la línea de base hasta el postratamiento en
cuanto a la gravedad de los síntomas de TEPT (p <.001) que persistió durante los segui-
mientos a los 3 y 6 meses con tamaños de efecto grandes (d de Cohen> 1,2); el 71% de los
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HIGHLIGHTS
• Current trauma-focused
treatment (TFT), including
prolonged exposure (PE),
usually lasts several months
with sessions being
delivered on a weekly basis.
• In this study, PE is
administered in an
accelerated way in chronic
PTSD patients with a likely
diagnosis of ICD-11 Complex
PTSD following multiple
interpersonal trauma and a
history of multiple
treatment attempts.
• The results of this open
study suggest that intensive
PE (iPE) can be effective.
Although previous
treatment attempts were
unsuccessful in these
patients, 71% showed
partial or complete response
during iPE. In addition, iPE
was found to be safe and
dropout rates were very low.
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participantes respondieron. Ninguno de los participantes abandonó durante la fase inten-
siva y solo el 5% lo hizo durante la fase de refuerzo. Los eventos adversos fueron extrema-
damente bajos y solo una minoría mostró exacerbación de los síntomas. El análisis de
clusters demostró cuatro trayectorias de respuesta al tratamiento: los que responden
rápidamente (13%), los que responden lentamente (26%), los que responden parcialmente
(32%) y los que no responden (29%). Se descubrió que las condiciones de vida y la
habituación al miedo entre sesiones predecían el resultado. Los participantes que vivían
solos eran más propensos a pertenecer a los que responden parcialmente que al grupo de los
que no responden, y los participantes que demostraron más habituación al miedo entre
sesiones tenían más probabilidades de pertenecer a los que responden rápidamente que al
grupo de los que no responden.
Conclusiones: los resultados de este estudio abierto sugieren que la EPI puede ser efectiva
en pacientes con TEPT con traumas interpersonales múltiples y después de múltiples
intentos previos de tratamiento. Además, en esta población de TEPT crónico, la EPI era
segura.
用于多次创伤和多次治疗后的长期 PTSD 患者的延长暴露疗法
背景：效果欠佳和高脱落率说明用于减轻创伤后应激障碍症状（PTSD）的创伤中心治
疗（TFT）的效果还有提升空间。
目标：探索用于长期 PTSD患者强化延长暴露（iPE）的效果和安全性。这些病人经历过多
次人际创伤，有多次治疗尝试，有可能被同时诊断为 ICD-11复杂 PTSD。
方法：被试（n=73）首先在四天时间里接受12次 X90分钟的 iPE疗程（强化阶段），随后
接受四次每周进行的90分钟增进延长暴露（PE）疗程（增强阶段）。在基线期、治疗后
和3月、6月后各评估一次主要结果——治疗师评估的 PTSD 症状严重度和诊断状况（临床
医生用 PTSD 量表；CAPS-IV）。识别治疗反应轨迹，并探索这些轨迹分类的预测指标。
结果：对 CAPS-IV 分数进行重复测量混合模型分析显示 PTSD 症状严重度从基线到治疗后
有所减轻（p <.001），并在3月和六月后的追踪期得到保持，症状减轻程度的效应量显著
（Cohen’s d > 1.2）。71%的被试在治疗后有所反应。没有被试在强化阶段脱落，只有5%
的被试在增强阶段脱落。负性事件非常少发生，只有 少数人出现了症状恶化。聚类分析
显示四个治疗反应轨迹：快速有效（13%），缓慢有效（26%），部分有效（32%）和无
效（29%）。生活质量和治疗间恐惧习惯化可以预测结果。独自居住的被试更有可能是部
分有效组（相较于无效组）；出现更多的治疗间恐惧性习惯化的被试更有可能是快速有
效组（相较于无效组）。
结论：这项开放研究的结果显示 iPE 可以有效地用于 有多次人际创伤和多次前期治疗尝
试的PTSD 病人。另外这种用于长期 PTD 人群的 iPE 是安全的。
1. Introduction
Trauma-focused treatment (TFT) programmes have
strong empirical support for their effectiveness in
ameliorating posttraumatic stress disorder (PTSD)
symptoms (Cusack et al., 2016). Still, a systematic
review of response in anxiety related disorders
showed that the average response rate for PTSD is
approximately 60% (Loerinc et al., 2015), although it
needs to be noted that definitions of treatment
response varied greatly across studies. In addition to
this suboptimal response, dropout rates in regular
TFT programmes are high. A meta-analysis investi-
gating dropout from PTSD treatment, including TFT
programmes and supportive counselling (Imel, Laska,
Jakupcak, & Simpson, 2013), estimated that, on aver-
age, 18% of patients drop out, with percentages vary-
ing significantly across studies and rates running up
to 52%, although definitions of dropout differed
among the studies.
To improve both response and dropout, TFT pro-
grammes have been augmented in various ways (de
Kleine, Rothbaum, & van Minnen, 2013; Kehle-Forbes
et al., 2013). However, these modifications have not
resulted in clinically significant improvement of either
outcome or dropout rates. A relatively new strategy is
to deliver the treatment sessions in a highly intensive
format (Hendriks, de Kleine, Hendriks, & van Minnen,
2016; Rauch & Rothbaum, 2016), with patients attend-
ing multiple sessions within a compact period of time
(e.g. within one week) instead of weekly sessions over
the course of several months. The main argument for
intensifying TFT is the expectation that it will improve
both outcome and dropout.
Indeed, a higher session frequency resulted in fas-
ter recovery in psychotherapy programmes in general
(Erekson, Lambert, & Eggett, 2015). Regarding TFT
programmes for PTSD, more specifically Cognitive
Processing Therapy (CPT) or Prolonged Exposure
(PE), higher session frequencies were associated
with significantly greater PTSD symptom ameliora-
tion even when controlling for the amount of sessions
(Gutner, Suvak, Sloan, & Resick, 2016). The authors
suggested that intensifying TFT may help reduce
avoidance of confronting the details of (situations
related to) the trauma memories. More theoretically,
results from animal studies about fear extinction
learning (i.e. the development of new associations
with the stimulus that inhibits the manifestation of
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the original fear memory and the presumed mechan-
ism of action of exposure therapy; see for an overview
Fitzgerald, Seemann, & Maren, 2014) showed that
once extinction learning is initiated in a massed
way, further extinction learning is more effective
when trials are spaced (Cain, Blouin, & Barad, 2003).
Additionally, highly intensive treatments may
improve dropout rates in the treatment of PTSD.
For instance, in the meta-analysis of Imel and collea-
gues (2013), variability in dropout rates across studies
was associated with the number of sessions delivered.
That is, in treatment programmes that encompassed
more (weekly) sessions, patients were more likely to
drop out. This suggests that shorter treatment dura-
tions might prove superior in retaining patients.
While treatment dropout is generally considered a
negative outcome, a recent study found that some
patients that prematurely ended CPT or PE never-
theless showed significant PTSD symptom ameliora-
tion, although having attended more treatment
sessions was associated with better treatment out-
comes (Szafranski, Smith, Gros, & Resick, 2017).
These findings suggest that, while it is important
that treatment duration is kept as short as possible
to prevent dropout and improve treatment outcome,
the total number of treatment sessions should not be
reduced.
Although abovementioned studies suggest that a
condensed TFT delivery format is a plausible strat-
egy to improve response and reduce dropout, the
effectiveness of these so-called intensive TFT pro-
grammes is still largely unknown. One study used a
brief imaginal exposure therapy (five daily 50-min-
ute sessions) to determine the augmentation effects
of methylene blue versus placebo and compared
outcomes to a waiting list condition that was later
converted into TFT delivered twice weekly. The
study provided preliminary evidence that intensive
imaginal exposure was effective, with results being
comparable to those obtained with regular treat-
ment with twice weekly sessions (Zoellner et al.,
2017). To our knowledge, only one randomized
controlled trial (RCT) directly compared intensive
TFT with TFT delivered in weekly sessions. This
study by Ehlers and colleagues (2014) showed that
an 18-hour intensive cognitive therapy delivered
within one week showed faster symptom reduction
and was equally effective in ameliorating PTSD
symptoms as regular weekly cognitive therapy for
patients suffering from PTSD following a single
trauma in adulthood. Additionally, the dropout
rate for the intensive programme was remarkably
low (3%), however, it must be mentioned that the
regular weekly cognitive therapy showed a compar-
able low dropout rate. The authors emphasized that
intensive TFT is of interest when treatment needs
to be conducted within a short period of time or
when patients themselves indicate a preference for
condensed treatment. However, the effectiveness of
highly intensive TFT for more complex patient
populations, such as patients with a history of
multiple childhood trauma or patients meeting the
symptoms of the ICD-11 diagnosis of complex
PTSD as proposed by the World Health
Organization (WHO; Maercker et al., 2013) that
includes PTSD symptoms as well as disturbances
in affect dysregulation, negative self-concept, and
interpersonal problems, is still largely unknown.
There is a lot of discussion about the treatment of
this so-called complex PTSD group, with some clin-
icians and researchers highlighting the importance of
tailoring treatments to this population, for example by
providing sequential or multicomponent therapies
instead of stand-alone TFT (Cloitre, 2015). Unlike
intensive TFT, this would imply treatments being
lengthened rather than shortened. Others argue that
the evidence for these sequential or multicomponent
interventions for complex PTSD patients is weak (de
Jongh et al., 2016). To bridge the knowledge gap con-
cerning the effectiveness of TFT for more complex
patient populations, we developed a highly intensive
TFT programme for those patients with a likely diag-
nosis of ICD-11 Complex PTSD after multiple inter-
personal trauma that had a history of multiple
treatment attempts as a next step in their treatment.
The intervention is offered in a massed format of 12 ×
90-minute sessions during four days and is based on
PE, a first line treatment for PTSD (Powers, Halpern,
Ferenschak, Gillihan, & Foa, 2010) and recommended
in available treatment guidelines (e.g. National
Institute for Health and Clinical Excellence
Guidelines on PTSD (NICE), 2005; International
Society for Traumatic Stress Studies, 2009).
In standard weekly TFT programmes, patients char-
acteristics are not found to be stable predictors of treat-
ment outcome (Ehlers et al., 2013; Ehring et al., 2014;
Powers et al., 2010; vanMinnen, Arntz, & Keijsers, 2002;
van Minnen, Harned, Zoellner, & Mills, 2012) and find-
ings concerning (early) treatment process variables, such
as fear habituation, are inconsistent (Bluett, Zoellner, &
Feeny, 2014; Sripada & Rauch, 2015; van Minnen &
Hagenaars, 2002). This variability might be explained
by the fact that in most studies prediction analyses of
associations were performed in entire and thus hetero-
geneous samples. In response to this methodology,
researchers recently identified several distinct trajec-
tories of treatment response based on change patterns,
suggesting there are disparate, more homogeneous,
response groups that might have differential predictors
(Allan, Gros, Myers, Korte, & Acierno, 2016; Clapp,
Kemp, Cox, & Tuerk, 2016; Galovski et al., 2016; Stein,
Dickstein, Schuster, Litz, & Resick, 2012).
The main purpose of the present open clinical trial
was to investigate whether the highly intensive
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prolonged exposure (iPE) programme would decrease
PTSD symptoms and dropout rates. Additionally, and
taking into account clinician-perceived barriers to PE in
terms of serious adverse events and symptom exacerba-
tion (van Minnen, Hendriks, & Olff, 2010), we also
evaluated treatment safety. Finally, to examine which
patients might benefit most from this iPE programme,
we aimed to identify distinct treatment response trajec-
tories and explored predictors of these response patterns.
2. Method
2.1. Participants
Participants (N = 73) were regular referrals to a Dutch
outpatient mental health clinic specialized in the treat-
ment of anxiety disorders (Figure 1). Inclusion criteria
were: (a) age ≥ 18 years; (b) history of multiple inter-
personal traumas (repeated sexual abuse and/or
repeated physical abuse); (c) meeting full DSM-IV-TR
(APA, 2000) diagnostic criteria for PTSD established
with the Clinician-Administered PTSD Scale (CAPS-
IV; Blake et al., 1995); and (d) history of multiple treat-
ment attempts. Exclusion criteria were: (a) suicide
attempt within eight weeks prior to study entry (i.e.
suicidality without imminent threat was not an exclu-
sion criterion); (b) inability to speak andwrite Dutch; (c)
severe intellectual impairment defined as an estimated
IQ of 70 or less; and (d) comorbid medical conditions
requiring more immediate care. Participants were
allowed to take psychotropic medication; those on med-
ication (76.7%) were asked to remain on a stable dosage.
2.2. Treatment
The iPE therapy programme (see Hendriks, de Kleine,
van Rees, Bult, & vanMinnen, 2010) was based on Foa’s
PE protocol (Foa, Hembree, & Rothbaum, 2007) with
the difference that, instead of weekly sessions, the
160 Assessed for eligibility
83 Excluded
26 Did not meet full PTSD 
criteria on CAPS-IV
7   Never previously received 
PTSD treatment
17 Met exclusion criteria
4 Involved in another 
research trial
3 Requested EAS
26 Did not continue
77 Eligible for trial
4 Did not continue
73 Entered into iPE and were 
included into assessments 
trajectory 
73 Completed intensive phase
69 Completed intensive phase
and at least 2 out of 4 
booster sessions
69 Completed posttreatment
63 Completed 3-mo follow-up 
59 Completed 6-mo follow-up 
73 Included in analysis
Figure 1. Flow diagram of patient recruitment and trial progress.
Note: CAPS-IV = Clinician-Administered PTSD Scale; EAS = euthanasia or assisted suicide; iPE = intensive prolonged exposure; mo = month;
PTSD = posttraumatic stress disorder.
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intervention was delivered in a highly intensive format.
Treatment started with a 90-minute session aimed at
psycho-education and case conceptualization, i.e. estab-
lishing a hierarchy of the four most relevant traumatic
experiences. The intensive phase consisted of four treat-
ment days delivered within one week. On each of the
four treatment days, the participants received three
daily individual 90-minute sessions (4.5 hours of treat-
ment per day). Every day, session 1 comprised pro-
longed imaginal exposure during which the
participant was asked to recount aloud the traumatic
memory as detailed and vividly as possible, with closed
eyes and in the present tense. Session 2 comprised
exposure with the participant being instructed to draw
the scene(s) of the hotspots of the traumatic memory,
each scene on a separate sheet of paper, including all
anxiety-provoking details of the hotspots in the drawing
(similarly to the instructions during the imaginal expo-
sure). Session 3 included exposure in vivo to trauma-
related situations and material. During this intensive
phase, patients did not receive any homework assign-
ments because of time constraints. After the intensive
phase, participants received four weekly 90-minute PE
booster sessions in combination with homework
assignments (booster phase) to promote a sound trans-
lation and generalization of treatment outcomes to
other contexts and everyday life. These booster sessions
each comprised prolonged imaginal exposure and
exposure in vivo, with homework assignments consist-
ing of listening to the audiotaped imaginal exposure of
the previous booster session, drawing the scene(s) of the
hotspots of the same traumatic memory, and continu-
ing exposure in vivo as practiced during the previous
booster session, all on a daily basis.
2.3. Procedure
This study was an open clinical trial and recruitment
took place between 2012 and 2015 (registered at
trialregister.nl; NTR5931). Patients completed a
screening with a therapist who assessed trauma char-
acteristics, PTSD diagnosis using the CAPS-IV (Blake
et al., 1995), psychiatric treatment history, and sui-
cidality using the MINI (Sheehan et al., 1998), to
determine the inclusion and exclusion criteria. The
DSM-IV Axis I diagnoses of any comorbid disorders
were also assessed with the MINI (Sheehan et al.,
1998). Eligible patients were invited to participate in
the study. Participants signed informed consent and
completed the baseline assessment.
2.4. Measures
The participants’ demographic characteristics were
recorded at baseline. Clinician-administered PTSD
diagnostic status and symptom severity (past week
version), as well as self-reported PTSD symptom
severity, were evaluated at baseline, posttreatment
(one week after the last booster session), and at
three- and six-month follow-up. In addition, self-
reported PTSD symptom severity was assessed at
each booster session.
Primary Outcome. Trained independent research
assistants (BSc or MSc in Psychology) interviewed
participants using the CAPS-IV (Blake et al., 1995),
a clinician-rated structured interview developed to
test for symptom severity as well as the presence of
a PTSD diagnosis. The CAPS-IV has excellent
internal consistency (Cronbach’s α = .94) and inter-
rater diagnostic agreement (Blake et al., 1995).
Interrater reliability for a PTSD diagnosis was
k = 0.92, and r = 0.99 for the total severity score
in our study (based on 10% randomly selected
interviews). Self-reported PTSD severity was mon-
itored using the Dutch translation of the PTSD
Symptom Scale, Self-Report (PSS-SR; Foa, Riggs,
Dancu, & Rothbaum, 1993), a 17-item question-
naire to rate the frequency of PTSD symptoms.
The internal consistency has been shown to be
high (Cronbach’s α = .91; Foa et al., 1993) and
the Dutch version has also shown to have good
internal consistency (Mol et al., 2005).
Dropout, Adversities and Symptom Exacerbation.
Dropout was recorded by the therapist; treatment
completion was defined as having completed the
intensive phase of the treatment (four weekdays)
and at least two of the four booster sessions. Serious
adverse events defined as any medical occurrence that
results in death, is life-threatening, requires inpatient
hospitalization, results in persistent or significant dis-
ability/incapacity, or requires intervention to prevent
permanent impairment, were reported. Furthermore,
participants reported suicidal ideation, self-harm,
aggressive behaviour, and the sense of losing control
on an 11-point Likert scale ranging from ‘no, not at
all’ (0) to ‘yes, very much’ (10), at baseline and at the
end of the intensive phase. Symptom exacerbation
was assessed by calculating PSS-SR difference scores
from baseline to booster 1 (deterioration during
intensive phase), from baseline to posttreatment
(deterioration during the treatment including the
booster phase), and from baseline to the six-month
follow-up. Symptom exacerbation was defined as an
increase of 7 or more points on the PSS-SR (Doane,
Feeny, & Zoellner, 2010).
Potential Predictors. Potential predictors of treat-
ment outcome were measured at baseline or early
treatment and all variables were treated as continuous
variables, unless otherwise indicated. Potential predic-
tors were assigned to one of three domains: (1) the
demographic domain: age, educational level (primary,
secondary, vocational, higher vocational education, or
university), and living condition (as a categorical vari-
able: living alone vs. together with partner or other
EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY 5
people like children or parents); (2) the clinical
domain: PTSD symptom severity as assessed using
the PSS-SR (Foa et al., 1993), depressive symptom
severity as measured with the Beck Depression
Inventory (BDI-II; Beck, Ward, Mendelson, Mock, &
Erbaugh, 1961), dissociative symptom severity as
assessed using the Dissociative Experiences Scale
(DES; Bernstein & Putnam, 1986), current severity of
borderline personality disorder manifestations as mea-
sured with the Borderline Personality Disorder symp-
tom checklist (BPD-47 symptom checklist; Arntz et al.,
2003), and psychoactive medication use (as a catego-
rical variable: yes, no); and (3) the fear habituation
domain: fear activation during the first exposure ses-
sion, calculated as the highest given Subjective Units of
Distress (SUD) rating (SUD peak) on a 0–10 point
scale (no anxiety to maximum anxiety), within-session
fear habituation during the first session, calculated as
SUD peakminus the latest SUD rating at the end of the
first exposure session, and between-session fear habi-
tuation, calculated as the difference between SUD peak
scores from the first and second imaginal exposure
session (Rauch, Foa, Furr, & Filip, 2004; van Minnen
& Hagenaars, 2002).
2.5. Therapist training and treatment fidelity
All participants were treated by a team of qualified
clinicians holding a master’s degree in clinical psy-
chology who were trained in PE therapy for PTSD; all
participated in twice-weekly group supervision ses-
sions with a senior therapist (AVM). Therapist adher-
ence to the treatment protocol was verified during the
supervision sessions and all deviations from the treat-
ment protocol during the intensive phase were docu-
mented and reported by the therapists after each
session. The treatment protocol had been violated
(e.g. no complete exposure during a session) in
2.1% of all treatment sessions (N = 876).
2.6. Data analysis
Treatment Effect. A mixed models procedure for
repeated measures analysis was conducted with sta-
tistical software (SPSS 22; IBM SPSS) to analyse
scores on the CAPS-IV and PSS-SR with time (base-
line, posttreatment, three- and six-month follow-up)
as the main fixed effect and an unstructured covar-
iance matrix for the repeated factor time. Effect sizes
were calculated for all analyses and interpreted using
Cohen’s (1988) criteria. Response on the CAPS-IV
(decrease from baseline of ≥ 10), loss of diagnosis
(response + no longer meeting ‘1/2’ symptom criteria
and CAPS-IV severity score < 45), and remission
(loss of diagnosis and CAPS-IV severity score < 20)
were calculated (Schnurr & Lunney, 2016). Also,
response and remission rates on the PSS-SR were
computed, where response was defined as a decrease
from baseline on the PSS-SR of 7 or more points
(Doane et al., 2010). Loss of diagnosis was defined
as a PSS-SR severity score ≤ 20, and remission was
defined as a PSS-SR severity score ≤ 10 (Cooper et al.,
2017).
Clustering Analysis. To investigate change patterns
during distinct stages of the treatment, classification
was based on response at four different time frames
to establish: (1) response to the intensive phase,
before the first booster session; (2) response during
the booster phase as determined by averaging the
scores of the four booster sessions to reflect the
process during the booster phase; (3) posttreatment
response; and (4) response at follow-up as established
by averaging the scores of the two follow-up assess-
ments. In accordance, four difference scores of self-
reported PTSD were computed: baseline score minus
booster 1 score (d1); baseline score minus mean score
of booster 1 to 4 (d2); baseline score minus posttreat-
ment score (d3); and baseline score minus the mean
score of the three- and six-month follow-ups (d4). To
deal with 17 missing values (6.2%) of these difference
scores, multiple imputation was applied (Basagaña,
Barrera-Gómez, Benet, Antó, & Garcia-Aymerich,
2013) using the R software package developed by
Buuren and Groothuis-Oudshoorn (MICE; 2011) to
obtain 100 imputed data sets. On these datasets,
k-Means cluster analysis (Steinley, 2006) was carried
out using the R software package developed by
Barrera-Gómez and Basagaña (MICLUST; 2013) to
identify clusters of similar patterns of PSS-SR scores.
In k-Means clustering an iterative process reallocates
participants to a certain number of clusters in order
to minimize the within-cluster variance. A squared
Euclidean distance metric was calculated to distribute
two-way, two-mode data (N objects each having mea-
surements on d1 to d4) into clusters such that the
distance for any object and the centroid of its respec-
tive cluster is at least as small as the distances to the
centroids of the remaining clusters. To gain insight
into response patterns beyond response or non-
response, we allowed the number of clusters to vary
between 3 and 6 and identified the optimal number
using CritCF as a goodness of fit measure to evaluate
the quality of each partition (Breaban & Luchian,
2011). After the final selection of clusters based on
CritCF, participants were allocated to the cluster they
were assigned to in most of the imputed data sets. As
a final step, the clusters were interpreted in terms of
average response (decrease from baseline on the PSS-
SR of 7 or more points; Doane et al., 2010), loss of
diagnosis, and remission (respectively defined as PSS-
SR ≤ 20 and PSS-SR < 10; Cooper et al., 2017).
Prediction Analysis. Multinomial logistic regression
analyses were conducted with statistical software
(SPSS 22; IBM SPSS) to investigate associations
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between potentially predictive variables and cluster (as
a nominal dependent variable with more than two
categories). Due to the explorative nature of the pre-
diction analysis, we aimed at generating (instead of
testing) hypotheses regarding the associations between
potential predictive variables and the clusters. In line
with previous work exploring predictors of outcome,
potential predictors were classified into different
domains and a stepwise procedure was used for each
predictor domain (de Kleine, Hendriks, Smits,
Broekman, & van Minnen, 2014; Fournier et al.,
2009). In step 1, a model including all variables for a
given domain was tested. The terms that were signifi-
cant at p < .20 were retained in step 2, where these
residual variables for this specific domain were tested
again. Subsequently, step 3 retained the terms from
step 2 that were significant at p < .10, and step 4
retained the terms from step 3 that were significant
at p < .05. Finally, all terms that were significant at
p < .05 at step 4 (within each domain) were included in
a final model (assessing predictors across all domains).
3. Results
Figure 1 shows the participant flow through the study.
The characteristics of the study population are pre-
sented in Table 1. From April 2012 through August
2015, 73 participants completed the baseline assess-
ment and started iPE. All participants had experienced
multiple interpersonal trauma, with the majority
reporting childhood (at age ≤ 16 years) abuse: 71.2%
childhood sexual abuse and 63.0% childhood physical
abuse. The participants were characterized by a cur-
rent medium to high suicide risk, severe posttrau-
matic, depressive, and dissociative symptoms, and
manifestations of borderline personality disorder. All
reported symptoms of complex PTSD (WHO ICD-11
criteria; Cloitre, Garvert, Brewin, Bryant, & Maercker,
2013), i.e. affect dysregulation, negative self-concept,
and interpersonal problems.
3.1. Treatment effects
The mixed model analysis revealed a main effect of
time on both the CAPS-IV (F(3,63) = 38.58, p < .001)
and the PSS-SR scores (F(3,60) = 35.84, p < .001).
There was a decrease in CAPS-IV and PSS-SR scores
between baseline and posttreatment that persisted
during the three- and six-month follow-ups with
large effect sizes (Table 2), reflecting an improvement
of clinically observed as well as self-reported PTSD
symptoms.
Response and remission rates with regard to
PTSD symptoms are listed in Table 3. Fifty-two
participants (71.2%) showed posttreatment response,
22 (30.1%) a loss of diagnosis, and 10 (13.7%)
achieved posttreatment remission according to the
CAPS-IV. A chi-square goodness-of-fit test indicated
that both loss of diagnosis and remission percen-
tages had further improved: loss of diagnosis at the
six-month follow-up χ2(1) = 7.92, p = .005, and
remission at the three- and six-month follow-ups,
χ2(1) = 5.68, p = .017. Based on self-reported PTSD
symptoms (PSS-SR), 43 participants (58.9%) showed
posttreatment response, 29 (39.7%) a loss of diag-
nosis, and 10 (13.7%) having achieved posttreatment
remission. A chi-square goodness-of-fit test indi-
cated that PSS-SR remission percentages had further
improved at three months (χ2(1) = 4.17, p = .041)
and at six months (χ2(1) = 5.68, p = .017).
Table 1. Characteristics of the study population (N = 73).
Characteristics
Age in years, mean (SD), range 35.9 (11.3), 19–63
Sex, n
Male 10
Female 63
Education, n (%)
Primary education 0 (0.0)
Secondary education 18 (24.7)
Vocational education 24 (32.9)
Higher vocational education 25 (34.2)
University 6 (8.2)
Living condition, n (%)
Alone 31 (42.5)
Together 42 (57.5)
Trauma history, n (%)
Childhood, ≤ 16 years
Multiple sexual abuse 52 (71.2)
Multiple physical abuse 46 (63.0)
Adulthood, > 16 years
Multiple sexual abuse 31 (42.5)
Multiple physical abuse 42 (57.5)
Time since trauma in years, mean (SD), range 28.2 (12.0), 6–59
Current medium or high suicide risk, n (%) 33 (48.5) a
CAPS-IV baseline, mean (SD), range 85.1 (17.2), 41–128
PSS-SR baseline, mean (SD), range 33.3 (6.5), 18–46 b
BDI-II baseline, mean (SD), range 30.6 (11.1), 0–51 b
DES baseline, mean (SD), range 22.7 (13.3), 0–56 c
DES baseline, score above clinical cut-off d,
n (%)
20 (32.8) c
BPD-47 baseline, mean (SD), range 103.7 (27.2), 51–203 b
BPD-47 subscales baseline, mean (SD), range
Affect dysregulation e 32.3 (9.0), 19–64 b
Negative self-concept f 20.1 (6.0), 8–36 b
Interpersonal problems g 7.4 (3.1), 3–15 b
Axis I and II comorbidity (current), n (%) 68 (93.2)
1–2 comorbid disorder 45 (61.6)
≥ 3 comorbid disorders 23 (31.5)
Comorbid depressive disorder, n (%) 50 (68.5)
At least one comorbid anxiety disorder, n (%) 23 (31.5)
At least one comorbid personality disorder,
n (%)
35 (47.9)
Receiving psychotropic medication, n (%) 56 (76.7)
Duration of PTSD in years, mean (SD), range 10.6 (9.7), 1–40
Note: BDI-II = Beck Depression Inventory Second Edition; BPD-
47 = Borderline Personality Disorder Checklist; CAPS-IV = Clinician-
Administered PTSD Scale; DES = Dissociative Experiences Scale; PSS-
SR = PTSD Symptom Scale, Self-Report; PTSD = posttraumatic stress
disorder.
a N = 68
b N = 69
c N = 61
d Clinical cut-off defined as a DES severity score of 25 (Boon & Draijer,
1993).
e Sum score of the ‘Mood’, ‘Impulsivity’, and ‘Anger’ subscales.
f As measured by the ‘Identity/Self-concept’ subscale.
g As measured by the ‘Relationships’ subscale.
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3.2. Dropout, adversities, and symptom
exacerbation
None of the participants dropped out during the
intensive phase and 95% completed the treatment
as defined as the intensive phase and at least two
booster sessions. During the iPE, a single serious
adverse event, a psychiatric hospitalization aimed at
suicide prevention, occurred. Paired-samples t-tests
showed no differences from baseline to the end of
the intensive phase in self-reported suicidal idea-
tion (baseline M = 2.3, SD = 2.8; post M = 2.2,
SD = 3.1), self-harm (baseline M = .8, SD = 2.0;
post M = .9, SD = 2.2), or aggressive behaviour
(baseline M = .2, SD = .9; post M = .2, SD = 1.1).
Sense of losing control decreased from baseline
(M = 4.5, SD = 3.0) to the end of the intensive
phase (M = 2.7, SD = 2.8), with the difference, 1.73,
BCa 95% CI [.97, 2.50] being significant t(66) = 4.52,
p < .001 and representing a medium effect size,
d = 0.59.
Two participants (2.7%) reported symptom
exacerbation on the PSS-SR from baseline to booster
1 (with one participant showing an increase of 7 and
the other an increase of 10 points), a third participant
from baseline to posttreatment (1.4%, increase of 17
points), while a fourth participant reported symptom
exacerbation from baseline to six-month follow-up
(1.4%, increase of 8 points).
3.3. Clustering analysis
Due tomissing baseline scores on the PSS-SR, it was not
possible to calculate difference scores for four partici-
pants who were, therefore, excluded from the cluster
analyses. Use of the CritCF criterion resulted in four
clusters: Fast responders (n = 9), Slow responders
(n = 18), Partial responders (n = 22), Non-responders
(n = 20). The Fast responders cluster consisted of parti-
cipants showing self-reported response and a loss of
diagnosis immediately after the intensive phase, i.e.
before starting the booster phase (average decrease of
19.8 on the PSS-SR, PSS-SR Mbefore booster phase = 15.7),
who additionally showed a second PSS-SR decrease
during the booster phase into remission (average
decrease of 29.4 on the PSS-SR from baseline; PSS-SR
Mafter booster phase = 6.0). Participants in the Slow respon-
ders cluster reported no response after the intensive
phase (average decrease of 5.7 on the PSS-SR, PSS-SR
Mbefore booster phase = 27.1), but did show a PSS-SR
response during the booster phase (average decrease
of 17.9 on the PSS-SR from baseline) and a loss of
diagnosis (PSS-SR Mafter booster phase = 14.9).
Participants classified in the Partial responders cluster
strictly reported no PSS-SR response during the inten-
sive phase (average decrease of 6.9 on the PSS-SR, PSS-
SR Mbefore booster phase = 26.4). However, their trajectory
is characterized by a PSS-SR response during the boos-
ter phase (average decrease of 9.5 on the PSS-SR from
baseline, PSS-SR Mafter booster phase = 23.7) and further
decreasing PSS-SR scores during the follow-up period
to a loss of diagnosis (PSS-SR M6 month follow-up = 18.7).
Finally, participants classified asNon-responders had no
change in PSS-SR scores at all (average increase of 2.2
on the PSS-SR from baseline to intensive phase, PSS-SR
Mbefore booster phase = 35.2, average increase of 0.9 on
the PSS-SR from baseline to post treatment, PSS-SR
Mafter booster phase= 33.9). Figure 2 shows the longitudinal
trajectories of the average PSS-SR scores within each
cluster.
3.4. Prediction analysis
Supplementary data are available online, providing
the results of the stepwise analyses for each of the
three domains: demographic characteristics, clinical
characteristics, and fear habituation characteristics.
Regarding the demographic characteristics, living
Table 2. Primary outcomes at baseline, posttreatment, three- and six-month follow-up a.
Outcome Baseline Posttreatment Three-month follow-up Six-month follow-up
CAPS-IV, mean (SD) 85.1 (17.2) 55.0 (30.8) 50.9 (32.9) 49.6 (30.9)
Effect size NA 1.21 1.30 b 1.42 b
PSS-SR, mean (SD) 33.3 (6.5) 21.7 (11.6) 21.1 (12.5) 20.3 (12.7)
Effect size NA 1.23 1.23 b 1.29 b
Note: CAPS-IV = Clinician-Administered PTSD Scale; PSS-SR = PTSD Symptom Scale, Self-Report.
a All outcomes reflect the estimated marginal mean from the mixed model analysis. Effect sizes are Cohen’s d based on estimated data from the mixed
model analysis.
b Effect sizes are based on follow-up compared to baseline scores.
Table 3. Observed response, loss of diagnosis, and remission
rates according to the CAPS-IV and PSS-SR.
Outcome Posttreatment
Three-month
follow-up
Six-month
follow-up
CAPS-IV a
Response, n (%) 52 (71.2) 54 (74.0) 58 (79.5)
Loss of
diagnosis, n (%)
22 (30.1) 29 (39.7) 33 (45.2)
Remission, n (%) 10 (13.7) 17 (23.3) 17 (23.3)
PSS-SR b
Response, n (%) 43 (58.9) 44 (60.3) 47 (64.4)
Loss of
diagnosis, n (%)
29 (39.7) 31 (42.5) 34 (46.6)
Remission, n (%) 10 (13.7) 16 (21.9) 17 (23.3)
Note: CAPS-IV = Clinician-Administered PTSD Scale; PSS-SR = PTSD
Symptom Scale, Self-Report.
a Response defined as decrease from baseline ≥ 10 points; loss of
diagnosis defined as response plus no longer meeting ‘1/2’ symptom
criteria plus a severity score < 45; remission defined as loss of diagnosis
plus a severity score < 20 (Schnurr & Lunney, 2016).
b Response defined as a decrease from baseline ≥ 7 points (Doane et al.,
2010); loss of diagnosis defined as a severity score ≤ 20; remission
defined as a severity score ≤ 10 (Cooper et al., 2017).
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condition was significantly associated with the Partial
responders cluster, predicting whether participants
belonged to the Partial responders cluster or to the
Non-responders cluster, b = −1.86, Wald χ2(1) = 7.27,
p = .007, indicating that participants living alone were
more likely to belong to the Partial responders cluster
than to the Non-responders cluster. Within the clin-
ical characteristics domain, no variables were signifi-
cantly associated with clusters. Results showed that,
within the fear habituation characteristics domain,
between-session fear habituation was significantly
associated with the Fast responders cluster. Between-
session fear habituation predicted whether partici-
pants belonged to the Fast responders cluster
(M = 1.42; 95% CI, -.09–2.92) or the Non-responders
cluster (M = .04; 95% CI, -.53–.61), b = .65, Wald χ2
(1) = 4.06, p = .044, indicating that participants
showing more between-session fear habituation
between the first and second imaginal exposure ses-
sion were more likely to belong to the Fast responders
cluster than to the Non-responders cluster.
Both significant terms were included in a final
model aimed at testing the associations between
each variable with cluster while controlling for the
other variable (Table 4). Living condition, b = −1.89,
Wald χ2(1) = 7.34, p = .007, and between-session fear
habituation, b = .76, Wald χ2(1) = 3.85, p = .050,
remained significant predictive variables.
4. Discussion
Overall, this study suggests, in line with previous
RCTs (Ehlers et al., 2014; Zoellner et al., 2017), that
PE delivered in an intensive format is effective for
PTSD patients. This is especially noteworthy given
that our sample mainly consisted of patients who
had experienced multiple childhood trauma and
reported symptoms of ICD-11 Complex PTSD,
expanding the evidence base for the effectiveness of
intensive TFT to a more complex patient population.
Additionally, all patients had received previous treat-
ments that had proven unsuccessful. Several studies
indicate that regular treatment attendance (Tarrier,
Sommerfield, Pilgrim, & Faragher, 2000) and a higher
frequency of sessions (Gutner et al., 2016), especially
early in the treatment, enhances treatment outcome.
One possible explanation for these findings is that
some PSTD patients have more trouble overcoming
their avoidance behaviour and, therefore, are in need
of a compact treatment programme instead of weekly
standard TFT that leave the patients more room to
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Figure 2. Average PTSD Symptom Scale, Self-Report (PSS-SR) scores before, during, and after treatment within each cluster.
Note: iPE = intensive prolonged exposure; Post = Posttreatment; PSS-SR = PTSD Symptom Scale, Self-Report; 3 FU = three-month follow-up; 6
FU = six-month follow-up. Average scores are based on completed assessments.
Table 4. Final model with all significant predictors from the
domain models.
95% CI for Odds Ratio
Predictor b (SE) a Lower
Odds
Ratio Upper
Cluster Fast responders
Living condition 1.19 (1.27) .27 3.29 39.69
Between-session fear
habituation
.76 (.39)**** 1.00 2.13 4.54
Cluster Slow responders
Living condition −.65 (.71) .13 .52 2.09
Between-session fear
habituation
−.06 (.25) .58 .94 1.53
Cluster Partial responders
Living condition −1.89 (.70)*** .04 .15 .59
Between-session fear
habituation
−.22 (.23) .51 .80 1.26
Note: SE = standard error.
a b-values represent unstandardized beta coefficients predicting the
chance to belong to one of the specified clusters relative to the Non-
responders cluster.
* p < .20; ** p < .10; *** p < .05; **** p = .05.
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engage in avoidance behaviour between sessions.
However, the results of our trial cannot support this
conclusion due to the lack of a control group. Future
controlled studies that monitor action readiness to
change avoidance before and during iPE and booster
sessions are needed.
Arguably, the lack of effect in previous treatments
might (also) be associated with the high dropout
rates, running up to 52% for conventional PTSD
interventions (Imel et al., 2013). In the present
study, all participants completed the intensive phase
and few patients (5%) left the booster phase prema-
turely. Again, overcoming avoidance behaviour by
delivering TFT treatment within a short time frame
may be the key mechanism underlying this results,
considering that early dropouts are also assumed to
prematurely discontinue treatment to avoid their
traumatic memories (Szafranski et al., 2017).
Although the low dropout rate in this study might
point to the fact that intensive TFT can prevent
dropout, we may also have included a select popula-
tion of patients for whom intensive treatment is
acceptable, which limits the generalizability of our
results.
Besides investigating the effects of iPE, it is impor-
tant to address potential risks of massed treatments.
A first concern here is that results achieved in a short
time might not be maintained in the long run, with
relapse as a result. We, however, found that the
posttreatment PTSD symptom amelioration persisted
up to six months. Second, TFT programmes may
evoke serious adverse events or symptom exacerba-
tions (Becker, Zayfert, & Anderson, 2004; van
Minnen et al., 2010) and these risks are assumed to
be higher in intensive treatment programmes and in
more vulnerable PTSD patients with ICD-11
Complex PTSD symptoms such as the present popu-
lation. We found no evidence for this assumption.
Our patients showed no serious adverse events dur-
ing the iPE in terms of suicide attempts and self-
reported PTSD symptom exacerbation was rare
(< 3%). Only one serious adverse event occurred in
terms of a hospitalization aimed at suicide preven-
tion. The low incidence of serious adverse events and
symptom exacerbation contributes to the growing
evidence that TFTs are safe (Larsen, Stirman, Smith,
& Resick, 2016), also if they are delivered in a massed
format.
The effectiveness, low dropout rate, and safety of
intensive TFT challenges (some) clinicians’ beliefs
that complex PTSD patients need tailored treatment
that includes an initial stabilization phase of emotion
regulation skills training (Cloitre, 2015; Dorrepaal
et al., 2013). The results of the present study provide
preliminary evidence that intensive stand-alone TFT
(without any preparatory or additional module(s))
and, more specifically, stand-alone intensive
exposure, is effective and safe for PTSD patients
with a likely diagnosis of ICD-11 Complex PTSD.
Our results may then contribute to the identification
of commonalities (in this case exposure) in the treat-
ment of PTSD and help us to distinguish the most
effective treatment components, enabling us to
improve the effectiveness of existing TFT pro-
grammes (Schnyder et al., 2015).
Although the response rate we obtained (71%)
was comparable to the average rate of 60% found
in a systematic review (Loerinc et al., 2015), as well
as to the response rates of studies with patient popu-
lations comparable to ours based on trauma charac-
teristics (Bohus et al., 2013; Cloitre et al., 2010;
Schnurr et al., 2007), not all participants improved
to the same degree. Our cluster analyses revealed
four distinct trajectories based on change patterns:
Fast, Slow, Partial, and Non-responders. Similar dis-
tinct response groups were also found by other
researchers (Allan et al., 2016; Clapp et al., 2016;
Galovski et al., 2016; Stein et al., 2012). We observed
that for a small proportion of responders (13%)
PTSD symptoms decreased immediately after com-
pleting the four days of iPE, i.e. before starting the
four-week booster phase in which exposure was
expanded to the full variety of contexts (Fast respon-
ders). The high dose of PE offered within a short
time frame may be the key mechanism underlying
the gains in this subgroup. This would be in line
with previous research showing that a higher fre-
quency of sessions, especially early in the treatment,
enhances treatment outcome (Gutner et al., 2016).
Next, we observed that 26% of the responders who
had not improved during the intensive phase did
show a major decrease in PTSD symptoms during
the booster phase (Slow responders). There are sev-
eral possible explanations for this finding. First, this
slow response trajectory may indicate that these
patients needed more sessions, which is in line with
previous findings showing that some patients need
additional sessions to benefit from PE (Foa et al.,
2005). Additionally or alternatively, the improve-
ment in this subgroup might not necessarily result
from the added exposure but rather from the spacing
of the additional exposure sessions during the boos-
ter phase. Animal studies (see Fitzgerald et al., 2014)
showed that, once initiated in a massed way, extinc-
tion learning is boosted when subsequent trials are
spaced (Cain et al., 2003). Third, the patients in this
cluster may have needed exposure in a variety of
contexts such as the home environment. It has
been suggested that greater variability in terms of
exposure contexts promotes generalization, resulting
in better treatment outcomes in anxious patients
(Craske, Treanor, Conway, Zbozinek, & Vervliet,
2014). In the third cluster (Partial responders), 32%
of the patients showed a partial improvement both
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during the intensive and the booster phase. This
distinct group was also found by others (Galovski
et al., 2016; Taylor et al., 2001). It is uncertain
whether here full recovery can be achieved with
additional therapy. Finally, of all our participants,
29% showed no response to treatment (Non-respon-
ders), reporting severe PTSD symptoms at all time
points. As other studies recorded a similar non-
responders cluster (Allan et al., 2016; Stein et al.,
2012), this raises the question whether, for some
patients, extinction learning is not feasible (Lissek
et al., 2005).
From a clinical perspective, it would be worthwhile
if we could determine in advance which patient is
likely and which patient is unlikely to respond to iPE.
We found that the patients showing more between-
session fear habituation between the first and second
imaginal exposure session were more likely to belong
to the Fast responders cluster than to the Non-
responders cluster. This is consistent with previous
findings (e.g. Cooper, Clifton, & Feeny, 2017) in
which between-session fear habituation, but not
within-session fear habituation, was found to be
related to treatment outcome. Although replication
is needed, our finding does suggest that a lack of
habituation to anxiety during the early stage of iPE
treatment can be used to detect those patients that are
unlikely to benefit from exposure-based treatment.
Also, patients living alone were more likely to belong
to the Partial-responders cluster than to the Non-
responders cluster, which result is in contrast to pre-
vious findings (Ehlers et al., 2013; Tarrier et al., 2000;
van Minnen et al., 2002). However, it is possible that
in our highly affected PTSD population, the presence
of a partner helps maintain PTSD-related avoidance
behaviour. Interestingly, none of the clinical variables
were found to be predictors of treatment response.
This is promising as it suggests that even patients
with (severe) comorbidity might benefit from inten-
sive TFT programmes like ours. Together, these find-
ings suggest that, contrary to what clinicians
generally assume, several baseline demographic and
clinical variables do not interfere with treatment and
are thus no robust contra-indicators of (intensive)
TFT interventions. We rather found that early treat-
ment process variables were better predictors of treat-
ment success.
Because our study lacks a control group and had
no randomized design, our findings warrant replica-
tion in a randomized controlled design. Additionally,
the results of the exploratory cluster and prediction
analyses should be interpreted with caution given the
low number of participants per cluster. Also,
although our participants had a history of multiple
treatment attempts, we did not use a standard mea-
sure to quantify the degree of treatment resistance per
participant (Dunlop, Kaye, Youngner, & Rothbaum,
2014). Another limitation is that we assessed suicidal
ideation, self-harm, aggressive behaviour, and a sense
of losing control with Likert scales rather than vali-
dated measures. Furthermore, we based therapist
adherence on self-reports instead of video observa-
tion. Lastly, we used the DSM-IV-TR (APA, 2000)
diagnostic criteria for PTSD and not the DSM-5
(APA, 2013). However, recent research showed that
the CAPS-IV diagnosis closely corresponds to the
CAPS-5 diagnosis, with most patients diagnosed
according to the DSM-IV criteria also meeting the
DSM-5 criteria for PTSD (Weathers et al., 2017). We
therefore assume that our results also apply to PTSD
populations diagnosed using the DSM-5 criteria.
Showing the effectiveness of intensive TFT for
PTSD, Ehlers et al. (2014) emphasized that an inten-
sive TFT is of interest when treatment needs to be
conducted within a short period of time or when
patients prefer a condensed treatment. Our results
expand these implications, suggesting that intensive
TFT is a feasible next step in the treatment of chronic
PTSD patients with a likely diagnosis of ICD-11
Complex PTSD following multiple interpersonal
trauma and a history of multiple treatment attempts.
However, also within our intensive TFT programme
not all participants improved and future research
regarding other next step options is needed.
5. Conclusion
Although randomized controlled trials are needed to
establish the effectiveness of iPE, this open study sug-
gests that iPE is both effective and safe in PTSD
patients having suffered multiple interpersonal child-
hood trauma and reporting ICD-11 Complex PTSD
symptoms. Despite previous treatment attempts being
unsuccessful, 71% of the patients showed partial or
complete response during iPE, with results being main-
tained up to six months. Serious adverse events and
symptom exacerbation were rare and dropout very low.
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